Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

U.S. Food and Drug Administration Approves Cangene's Anti-Hepatitis B Product, Winnipeg Company Says

January 31, 2006

On Monday, Cangene Corp. said the Food and Drug Administration has approved its HepaGam B treatment for hepatitis B virus (HBV) for sale in the United States. The drug has been approved for treatment of acute exposure to blood containing HBV surface antigen, perinatal exposure of infants born to infected mothers, and sexual and household exposure to infected persons. Winnipeg-based Cangene expects HepaGam B will be launched within a few months and be distributed by Apotex Corp.

Back to other news for January 31, 2006

Adapted from:
Canadian Press
01.30.06


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More HIV News
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement